Optimization of novel phenotypic screening hits for treatment of Malaria
用于治疗疟疾的新型表型筛选靶标的优化
基本信息
- 批准号:10376179
- 负责人:
- 金额:$ 73.72万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-04-01 至 2026-03-31
- 项目状态:未结题
- 来源:
- 关键词:ADME StudyAfricanAmes AssayAmidesAntimalarialsBiochemicalBiologicalBiological AssayBiologyBloodCell LineCellsCessation of lifeChemicalsChemistryChemopreventionChildClinicalCommunicable DiseasesDataDevelopmentDiseaseDoseDrug KineticsDrug resistanceErythrocytesEvaluationExcretory functionGeneticGoalsHalf-LifeHepG2HumanHuman Cell LineIn VitroInsecticidesIon ChannelKineticsLeadLife Cycle StagesLiverMalariaMammalian CellMass Spectrum AnalysisMeasuresMedicineMetabolicMetabolismModelingMolecular TargetMusParasite resistanceParasitesParentsPharmaceutical ChemistryPharmaceutical PreparationsPhenotypePlasmodiumPlasmodium falciparumPlasmodium vivaxPopulationPositioning AttributeProcessPropertyProteomicsProtocols documentationPublishingRattusRecrudescencesResistanceRiskSCID MiceSafetySeriesSolubilityStructureTestingTetrazolesTimeVaccinesValidationWorkabsorptionanalogazetidinebaseclinical candidateclinical developmentcombatcomparative efficacycrosslinkdrug candidatedrug discoverydrug-sensitiveexperiencegenome sequencinghigh throughput screeninghuman diseasein vivoinsightlead optimizationmortalitymouse modelmultidisciplinarynovelnovel therapeuticspiperidinepre-clinicalpreclinical developmentpressureprogramssafety assessmentscaffoldscreeningsmall molecule librariestransmission processwhole genome
项目摘要
Project Summary.
Malaria remains one of the most serious infectious diseases, globally threatening nearly 50% of the world
population, and leading to >400,000 deaths annually, mostly among young African children. There are no
effective vaccines and the disease is managed through a combination of insecticides and drugs for both
treatment and chemoprevention. The relentless ability of the parasite to acquire drug resistance necessitates
that a continual pipeline of new drug candidates is maintained. We sought to identify novel chemical starting
points for the discovery of new anti-malarial drugs by phenotypic screening against erythrocytic stage P.
falciparum. We undertook a high-throughput screen of a newly acquired (in 2017) 100K chemical library
reasoning that since it was recently purchased it might contain new chemical space that had not been previously
screened. As part of our hit validation process we prioritized hits from the screen based on the following
experimental measures: 1) potency versus the parasite against two cell lines, 2) selectivity versus a human cell
line, 3) novelty of the chemical matter, 4) parasite kill rate (medium and fast kill being desirable) and 5) in vitro
ADME properties including metabolic stability and solubility. We identified 16 chemical series that met our
objectives of novelty and from these have selected 3 series for hit to lead chemistry. These include a piperidine
carboxamide series (Alchm18) that has a moderate rate of kill, good starting potency (P. falciparum 3D7 EC50
<100 nM), and strong starting in vitro and in vivo ADME properties; a a tetrazole-based series (Alchm3) that
shows fast kill kinetics, and a an azetidine amide (Alchm17), with good potency and solubility. We have validated
synthetic strategies for all three series through synthesis of both the parent compound and analogs. The goal
of this proposal is to conduct hit-to-lead chemistry on these three series, to evaluate their biological profiles,
and to perform studies to identify their targets. The strongest series will then be prioritized for full scale lead
optimization. Our project team of Phillips (parasite biology), Ready (medicinal chemistry) and Charman
(ADME/PK) is highly experienced and has a long track record of working together. The project will also be a
collaborative effort with the Medicines for Malaria Venture (MMV) who will provide in kind support and access
to their in vitro and in vivo parasite efficacy models and project oversight. Upon completion of this proposal we
will have substantial new insight into the developability of three new chemical series, we will have validated up
to three additional new anti-malarial targets, and we will have progressed the strongest of our three chemical
series through lead optimization to identify a potential preclinical development candidate.
项目摘要。
疟疾仍然是最严重的传染病之一,在全球范围内威胁着全球近50%的人口
这一疾病每年造成40多万人死亡,其中大多数是非洲儿童。没有
有效的疫苗和疾病是通过杀虫剂和药物的组合管理,
治疗和化学预防。寄生虫获得抗药性的无情能力
保持新药候选药物的持续供应。我们试图找出新的化学物质,
通过针对红细胞P期的表型筛选发现新的抗疟疾药物的要点。
恶性疟原虫。我们对新获得的(2017年)100 K化学文库进行了高通量筛选
推理,因为它是最近购买的,它可能含有以前没有的新化学空间,
筛选出作为命中验证过程的一部分,我们根据以下内容对屏幕上的命中进行优先级排序
实验测量:1)针对两种细胞系对抗寄生虫的效力,2)针对人细胞的选择性
线,3)化学物质的新奇,4)寄生虫杀灭率(期望中等和快速杀灭)和5)体外
ADME性质,包括代谢稳定性和溶解性。我们确定了16个化学系列,
新奇的目标,并从这些选择了3个系列的命中导致化学。这些包括哌啶
甲酰胺系列(Alchm 18)具有中等的杀灭率、良好的起始效力(恶性疟原虫3D 7 EC 50
<100 nM),以及强的体外和体内ADME起始性质;基于四唑的系列(Alchm 3),
显示出快速的杀灭动力学,以及具有良好效力和溶解性的氮杂环丁烷酰胺(Alchm 17)。我们已经验证
通过母体化合物和类似物的合成,所有三个系列的合成策略。目标
该提案的一个重要目的是对这三个系列进行命中-铅化学,以评估其生物学特征,
并进行研究以确定其目标。最强的系列将被优先考虑全面领先
优化.我们的项目团队菲利普斯(寄生虫生物学),准备(药物化学)和查曼
(ADME/PK)经验丰富,有着长期的合作记录。该项目也将是一个
与疟疾药物研发公司(MMV)合作,后者将提供实物支持和获取
他们的体外和体内寄生虫功效模型和项目监督。在完成这项建议后,我们
我们将对三个新化学系列的可开发性有实质性的新见解,我们将验证
三种新的抗疟疾靶点,我们将在三种化学物质中最强的一种上取得进展,
系列通过铅优化,以确定潜在的临床前开发候选。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Margaret A. Phillips其他文献
Role of the prodomain in folding and secretion of rat pancreatic carboxypeptidase A1.
前结构域在大鼠胰腺羧肽酶 A1 折叠和分泌中的作用。
- DOI:
- 发表时间:
1996 - 期刊:
- 影响因子:2.9
- 作者:
Margaret A. Phillips;William J. Rutter - 通讯作者:
William J. Rutter
Cloning and sequencing of the ornithine decarboxylase gene from Trypanosoma brucei. Implications for enzyme turnover and selective difluoromethylornithine inhibition.
布氏锥虫鸟氨酸脱羧酶基因的克隆和测序。
- DOI:
- 发表时间:
1987 - 期刊:
- 影响因子:4.8
- 作者:
Margaret A. Phillips;P. Coffino;Chao Wang - 通讯作者:
Chao Wang
Margaret A. Phillips的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Margaret A. Phillips', 18)}}的其他基金
Optimization of novel phenotypic screening hits for treatment of Malaria
用于治疗疟疾的新型表型筛选靶标的优化
- 批准号:
10652726 - 财政年份:2021
- 资助金额:
$ 73.72万 - 项目类别:
Optimization of novel phenotypic screening hits for treatment of Malaria
用于治疗疟疾的新型表型筛选靶标的优化
- 批准号:
10594538 - 财政年份:2021
- 资助金额:
$ 73.72万 - 项目类别:
Optimization of novel phenotypic screening hits for treatment of Malaria
用于治疗疟疾的新型表型筛选靶标的优化
- 批准号:
10721415 - 财政年份:2021
- 资助金额:
$ 73.72万 - 项目类别:
Lead optimization of DHODH inhibitors for malaria
疟疾 DHODH 抑制剂的先导优化
- 批准号:
8601042 - 财政年份:2013
- 资助金额:
$ 73.72万 - 项目类别:
Lead Optimization of DHODH Inhibitors for Malaria
疟疾 DHODH 抑制剂的先导优化
- 批准号:
10736209 - 财政年份:2013
- 资助金额:
$ 73.72万 - 项目类别:
Lead optimization of DHODH inhibitors for malaria
疟疾 DHODH 抑制剂的先导优化
- 批准号:
8440181 - 财政年份:2013
- 资助金额:
$ 73.72万 - 项目类别:
Lead optimization of DHODH inhibitors for malaria
疟疾 DHODH 抑制剂的先导优化
- 批准号:
8975598 - 财政年份:2013
- 资助金额:
$ 73.72万 - 项目类别:
Lead optimization of DHODH inhibitors for malaria
疟疾 DHODH 抑制剂的先导优化
- 批准号:
8776264 - 财政年份:2013
- 资助金额:
$ 73.72万 - 项目类别:
相似海外基金
Tracing the African roots of Sri-Lanka Portuguese
追溯斯里兰卡葡萄牙语的非洲根源
- 批准号:
AH/Z505717/1 - 财政年份:2024
- 资助金额:
$ 73.72万 - 项目类别:
Research Grant
Bovine herpesvirus 4 as a vaccine platform for African swine fever virus antigens in pigs
牛疱疹病毒 4 作为猪非洲猪瘟病毒抗原的疫苗平台
- 批准号:
BB/Y006224/1 - 财政年份:2024
- 资助金额:
$ 73.72万 - 项目类别:
Research Grant
Commercialisation of African Youth Enterprise Programme
非洲青年企业计划商业化
- 批准号:
ES/Y010752/1 - 财政年份:2024
- 资助金额:
$ 73.72万 - 项目类别:
Research Grant
Resilient and Equitable Nature-based Pathways in Southern African Rangelands (REPAiR)
南部非洲牧场弹性且公平的基于自然的途径 (REPAiR)
- 批准号:
NE/Z503459/1 - 财政年份:2024
- 资助金额:
$ 73.72万 - 项目类别:
Research Grant
Evaluating the effectiveness and sustainability of integrating helminth control with seasonal malaria chemoprevention in West African children
评估西非儿童蠕虫控制与季节性疟疾化学预防相结合的有效性和可持续性
- 批准号:
MR/X023133/1 - 财政年份:2024
- 资助金额:
$ 73.72万 - 项目类别:
Fellowship
Understanding differences in host responses to African swine fever virus
了解宿主对非洲猪瘟病毒反应的差异
- 批准号:
BB/Z514457/1 - 财政年份:2024
- 资助金额:
$ 73.72万 - 项目类别:
Fellowship
The impact on human health of restoring degraded African drylands
恢复退化的非洲旱地对人类健康的影响
- 批准号:
MR/Y019806/1 - 财政年份:2024
- 资助金额:
$ 73.72万 - 项目类别:
Research Grant
CAREER: Habitability of the Hadean Earth - A South African perspective
职业:冥古宙地球的宜居性——南非的视角
- 批准号:
2336044 - 财政年份:2024
- 资助金额:
$ 73.72万 - 项目类别:
Continuing Grant
Nowcasting with Artificial Intelligence for African Rainfall: NAIAR
利用人工智能预测非洲降雨量:NAIAR
- 批准号:
NE/Y000420/1 - 财政年份:2024
- 资助金额:
$ 73.72万 - 项目类别:
Research Grant
Assessing the role of the lithospheric mantle during passive margin development - insights from the South Atlantic African margin
评估岩石圈地幔在被动边缘发育过程中的作用 - 来自南大西洋非洲边缘的见解
- 批准号:
2305552 - 财政年份:2024
- 资助金额:
$ 73.72万 - 项目类别:
Standard Grant














{{item.name}}会员




